The results of the MS-SMART trial, an innovative trial testing multiple drugs at the same time, have ruled out three repurposed drugs for the treatment of progressive MS.
A phase II clinical trial has shown ibudilast, a repurposed asthma medication, can slow down the rate of brain tissue loss in progressive MS by almost half compared to a placebo treatment.
Genetic screening of people with primary progressive MS has shown that four rare genetic changes, which are known to cause other neurological diseases, may play a role in primary progressive MS.
Researchers, clinicians and people living with MS, from around the world converged on the city of Toronto in Canada for the 3rd Congress of the International Progressive MS Alliance.
How the biological processes cause progression in different types of MS.
A new, international clinical trial has shown that siponimod can slow progression in people with secondary progressive MS.
Screening of almost 250 medications has identified clomipramine as a possible treatment for progressive MS.
The European Commission has approved the first disease-modifying therapy, ocrelizumab, for early primary progressive MS (PPMS).
The EMA has recommended that ocrelizumab (Ocrevus), the first disease-modifying treatment for primary progressive MS (PPMS), be prescribed for adults with early primary progressive MS